【摘要】目的 观察地特胰岛素或甘精胰岛素联合门冬胰岛素治疗2型糖尿病的有效性及安全性。方法64例2型糖尿病患者随机分为地特胰岛素联合门冬胰岛素组(Det 组)和甘精胰岛素联合门冬胰岛素组(Gla 组)，治疗3个月。结果3个月后，两组HbA1C分别由8.8%、8.9%降至7.0%，FPG分别由11.2、10.9mmo/l降至6.2、6.1mmol/l，2hPG分别由13.6、13.8mmol/l降至8.1、8.2mmol/l，差异有统计学意义(P<0.05)。低血糖的发生率分别为5.9%和6.0%，体重增加分别为(1.3±0.4)kg和(2.5±0.3)kg，Det 组体重增加明显低于Gla组(P<0.01)。 结论 地特胰岛素或甘精胰岛素联合门冬胰岛素均可有效控制血糖，地特胰岛素在减少体重增加方面更有优势。

　　【关键词】地特胰岛素;甘精胰岛素;门冬胰岛素;2型糖尿病

　　Clinical observation on the insulin detemir or insulin glargine in combination with insulin aspart in the treatment for type 2 diabetes ZHEN Yue-qiao1, MA Yun-zhi2. 1. Department of Endocrinology, the Fifth Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, China; 2. Department of Endocrinology, Zoucheng People,s Hospital, Zoucheng 273500,China

　　　【Abstract】Objective To observe the efficacy and safety of insulin detemir or insulin glargine in combination with insulin aspart in the treatment for type 2 diabetes. Methods Six-four type 2 diabetic patients were randomized into two groups, which were treated by insulin detemir + insulin aspart (Det group) and insulin glargine + insulin aspart (Gla group) respectively for 3 months. Results After 3 months, the HbA1C of the two groups decreased respectively from 8.8% and 8.9% to 7.0%, the FPG decreased respectively from 11.2 and 10.9 to 6.2 and 6.1mmol/l, and the 2hPG decreased respectively from 13.6 and 13.8 to 8.1 and 8.2mmol/l, and the difference was statistically significant (P<0.05). The incidence of hypoglycemia of the two groups was 5.9% and 6.0% respectively. The gaining of body weight of the two groups was (1.3±0.4)kg and (2.5±0.3)kg respectively, the Det group was significantly lower than the Gla group (P<0.01). Conclusion Both insulin detemir and insulin glargine are effective and safe in the glycemic control, while the former is superior to the latter in less gaining of body weight.

　　【Key words】Insulin detemir; Insulin glargine; Insulin aspart; Diabetic mellitus, type 2